Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.23 USD
Change Today +0.03 / 0.71%
Volume 16.5K
CEMI On Other Exchanges
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

chembio diagnostics inc (CEMI) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/12/15 - $5.25
52 Week Low
08/26/15 - $3.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

chembio diagnostics inc (CEMI) Related Businessweek News

No Related Businessweek News Found

chembio diagnostics inc (CEMI) Details

Chembio Diagnostics, Inc., together with its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care diagnostic tests that detect infectious diseases. It offers rapid tests for the detection of HIV and syphilis antibodies. The company’s products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV Test, which detect antibodies to HIV 1 and 2 with visually interpreted results; a Syphilis multiplex test for the detection of antibodies to HIV and Syphilis; and a rapid test for the detection of Hepatitis-C antibodies. Chembio Diagnostics, Inc. sells its products under STAT PAK, SURE CHECK, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with the Oswaldo Cruz Foundation relating to products based on its DPP technology products; and the Centers for Disease Control and Prevention to develop and validate DPP Ebola and DPP Febrile Illness Assays. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

166 Employees
Last Reported Date: 03/5/15
Founded in 1985

chembio diagnostics inc (CEMI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $298.6K
Chief Operating Officer
Total Annual Compensation: $334.6K
Chief Science & Technology Officer
Total Annual Compensation: $405.0K
Compensation as of Fiscal Year 2014.

chembio diagnostics inc (CEMI) Key Developments

Chembio Diagnostics Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Chembio Diagnostics Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, loss from operations was USD 897,971 compared with USD 232,865 for the prior year period. The company recorded a net loss of USD 664,000 or USD 0.07 per diluted share compared with a lower net loss of USD 146,000 or USD 0.02 per diluted share for the prior-year same period. Total revenues were USD 6.72 million, a decline of 9.5% from total revenues of USD 7.42 million in the prior-year same period. For the six months, the company reported net loss was USD 1,310,902 or USD 0.14 per diluted share, compared with USD 370,720 or USD 0.04 per diluted share for the prior year period. Total revenues were USD 12,947,295 against USD 13,235,670 in the prior year period. Loss from operations was USD 1,773,463 compared with USD 615,604 for the prior year period. Net cash used in operating activities of USD 2,166,001 against USD 2,535,529 a year ago.

Chembio Diagnostics, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Chembio Diagnostics, Inc. announced that they will report Q2, 2015 results Pre-Market on Aug 06, 2015

Chembio Diagnostics, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Chembio Diagnostics, Inc., Q2 2015 Earnings Call, Aug 06, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEMI:US $4.23 USD +0.03

CEMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $51.85 USD +0.65
Bio-Rad Laboratories Inc $137.02 USD +2.54
MedMira Inc C$0.04 CAD 0.00
OraSure Technologies Inc $5.39 USD +0.07
Trinity Biotech PLC $14.14 USD -0.12
View Industry Companies

Industry Analysis


Industry Average

Valuation CEMI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHEMBIO DIAGNOSTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at